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Abstract
Background: There is evidence that the immune systems of patients with breast cancer are
dysfunctional. Regulatory T cells (Tregs), and IDO, an immunosuppressive enzyme, are associated
with more advanced disease in some cancers and may promote immunologic tolerance to tumors.
Our aim was to assess whether expression of Foxp3, a marker of Tregs, and IDO were linked with
nodal metastasis in breast cancer patients. Inhibitors of IDO are available and could potentially
demonstrate utility in breast cancer if IDO drives progression of disease.
Methods: Sentinel lymph nodes (SLN) of 47 breast cancer patients with varying degrees of nodal
disease and 10 controls were evaluated for expression of Foxp3 and IDO using
immunohistochemistry. Positively stained cells were quantified and their distribution within the
SLN noted.
Results: The proportion of Foxp3+ cells was higher in SLN of cancer patients than controls (19%
v. 10%, p < 0.001). Specifically, there were more Foxp3+ cells in SLN with metastasis than tumor-
free SLN (20% v. 14%, p = 0.02). The proportion IDO+ cell in SLN of cancer patients was not
statistically different than controls (4.0% v. 1.6%, p = 0.08). In order to demonstrate the combined
immunosuppressive effect of Foxp3 and IDO, we categorized each SLN as positive or negative for
Foxp3 and IDO. The Foxp3+/IDO+ group almost exclusively consisted of cancer patients with node
positive disease.
Conclusion: In conclusion, our study shows that Foxp3+ cells are associated with more advanced
disease in breast cancer, a finding that is proving to be true in many other cancers. As IDO has been
found to promote differentiation of Tregs, IDO may become a suitable target to abrogate the
development of T-cell tolerance and to promote an effective immune response to breast cancer.
Our results about the combined expression of IDO and Foxp3 in metastastic SLN support this
assumption.
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Background
By the time cancer is clinically detectable tumors have
likely developed mechanisms to escape immunosurveil-
lance, and increasing evidence suggests that regulatory T-
cells (Tregs) have a major role in modulating host
response to tumor. Tregs are produced in the thymus and
they act in the periphery to control potentially hazardous
self-reactive effector cells that have escaped thymic nega-
tive selection[1]. The exact mechanism of suppression is
not yet determined; however, direct cellular contact is
required. Regardless, it has been shown that accumulation
of Tregs in tumor, as measured by Foxp3 expression, has
been associated with a worse prognosis in patients with
ovarian cancer[2,3]. In esophageal and gastric cancers
higher populations of tumor infiltrating Tregs were asso-
ciated with more advance disease[4]. Further evidence for
the role of Tregs in tumor-specific immunosuppression is
seen in murine models where depletion of Tregs promotes
an effective antitumor response[5].
Indolamine 2,3-dioxygenase (IDO) is a tryptophan
degrading-enzyme that inhibits T-cell proliferation. IDO
is expressed by trophoblasts, dendritic cells[6] and macro-
phages[7]. IDO has been found to prevent fetal rejec-
tion[8], and it is suspected that it may promote tolerance
to tumors[9]. There is evidence that there is increased
expression of IDO in the primary tumor and serum of
patients with breast cancer[10], and that higher levels of
IDO expression in colorectal carcinoma represent a poor
prognostic factor[11]. Additionally, expression of IDO by
leukemic cells in acute myeloid leukemia has been shown
to induce Foxp3+ Tregs[12]. The role of IDO has been con-
sidered relevant enough that inhibitors of IDO are being
developed for clinical trials[13]. These inhibitors could
potentially demonstrate utility in breast cancer if IDO
promotes progression of disease.
Metastasis to lymph nodes is one of the strongest predic-
tors of survival in patients with breast cancer [14-16]. Axil-
lary clearance for lymph node evaluation has been
replaced by sentinel lymph node biopsy at many centers
in the setting of the appropriate clinical stage[17].
Improved selectivity in lymph node dissection has
resulted in a more detailed analysis of the removed nodes,
and greater attention is being paid to the immune status
of these nodes. Sentinel lymph nodes (SLN) are unique in
that they represent both the sites of T-cell activation and
early metastasis. As such, these nodes are ideal for investi-
gations of tumor immunology in breast cancer.
Recent reports have shown that the immune systems of
patients with breast cancer are dysfunctional[18]. There-
fore, we set out to find evidence of immunosuppression in
the SLN of patients with breast cancer. We hypothesized
that the expression of Foxp3 and IDO within SLN were
associated with nodal metastasis.
Methods
We used SLN of 47 breast cancer patients treated at the
Breast Surgery Unit of Helsinki University Hospital
between 2001 and 2003. A prospectively collected data-
base was searched to select patients with node negative
disease as well as micro- and macro-metastasis. Another
criterion was to include patients that also had non-SLN
harvested. These patients had either tumor negative SLN
(n = 11), SLN with micrometastases (n = 16), or SLN with
macrometastases (n = 20) as defined by the International
Union Against Cancer (UICC) TNM classification sys-
tem[19]. The clinicopathological data of the breast cancer
patients included in this study are summarized in Table 1.
SLN from 10 control patients with SLN biopsy due to a
false-positive preoperative biopsy, either core needle
biopsy or fine needle aspiration cytology, were used as
controls. These control patients had premalignant condi-
tions such as lobular neoplasia in situ or atypical ductal
hyperplasia, but not ductal carcinoma in situ or invasive
breast cancer. This project was approved by the Ethics
Committee of Helsinki University Central Hospital.
Table 1: Patient and Tumor Characteristics
Node-positive Node-negative
Number 36 11
Age* 60 (49–70) 54 (48–70)
Type
Ductal 20 5
Lobular 15 3
Other 2 3
Tumor Size (mm)* 16 (14–23) 17 (14–22)
Tumor Stage
T1b 5 1
T1c 22 6
T2 12 5
Tumor Grade
I8 4
II 24 3
III 4 4
ER
Positive 34 9
Negative 2 2
PR
Positive 23 8
Negative 13 3
MIB-1
Positive 15 5
Negative 21 6
There were no statistically significant differences between the groups.
ER = estrogen receptor, PR = progesterone receptor, MIB-1 = 
proliferation index.
* median (range)BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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The SLN were assessed using serial sectioning and immu-
nohistochemistry[20,21]. One representative tissue block
was selected for immunohistochemical studies upon eval-
uation of all available material.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded lymph nodes were
sectioned into 3–4 μm slices and affixed on glass slides.
After the samples were heated for half an hour at 56°C,
they were deparaffinized in xylene, rehydrated in a graded
alcohol series, and washed in water. For antigen retrieval,
samples were microwaved for a total of 20 minutes in a
citrate buffer (pH = 6). Endogenous peroxidase activity
was quenched in a bath of methanol and hydrogen perox-
ide for 30 minutes. Samples were incubated overnight at
4°Celsius with Foxp3 antibodies (Nordic Biosite AB Täby,
Sweden) and IDO antibodies (Millipore Oy Espoo, Fin-
land) at concentrations of 1:1000 and 1:100, respectively.
These antibodies were detected with Vectastain Elite ABC
Rat IgG kit (Vector Burlingame, CA). Samples were incu-
bated overnight at 4°Celsius with CD3 (Dako, Denmark)
and CD4 (Novocastra, Great Britain) antibodies at con-
centrations of 1:300 and 1:25, respectively, and were
detected with Envision Advance-Kit (Dako, Denmark). All
samples were counterstained with Harris Hemotoxylin for
30 seconds and mounted. Samples were run in batches
with as many as 19 at a time. Batches contained a mixture
of controls, node negatives and node positives.
Positively stained cells in the non-metastatic regions of
the lymph nodes were quantified as a percentage of all
cells in a minimum of three high-powered fields (400×
magnification), and averaged. In some cases, fewer fields
were able to account for all of the positive staining. Non-
metastatic regions were used to allow comparison of lym-
phocytes between patients with and without metastasis. A
Nikon eclipse 80i microscope was used for data analysis
and image acquisition.
Statistics
JMP (SAS Institute Inc., USA) was used for statistical anal-
ysis. Basic statistics were used to analyze our grouped data.
Since the data are non-parametric, the Kruskal-Wallis and
the Mann-Whitney U tests were used to compare the
expression of each stain amongst the groups. For the
stains with statistically significant differences in expres-
sion, multiple pairwise comparisons were made using
Wilcoxon's rank sum test. Spearman's rank-order test was
used to assess for correlations between each stain and clin-
icopathologic data. Logistic regression analyses were per-
formed to assess the predictive effect each stain had on
nodal status.
The Foxp3 and IDO stainings were divided into negative
and positive groups according to their medians. These cut-
offs were used to form four nodal-suppression profiles:
Foxp3+/IDO+, Foxp3+/IDO-, Foxp3-/IDO+, and Foxp3-/
IDO-. The proportions of patients in these four categories
of SLN were then compared between the node-positive
and the node-negative cancer patients and the controls
using χ2 statistical test.
Results
Foxp3+ lymphocytes are located in the paracortex of SLN
Foxp3+ cells were morphologically small lymphocytes and
were distributed in the typical T-cell areas, namely the
paracortical regions of SLN, Figure 1. The localization was
similar in SLN from the cancer patients and the controls.
Metastatic SLN of cancer patients are enriched with 
Foxp3+ cells
The relative frequency of Foxp3+ cells was higher in cancer
patients, median 19%, range 8–37%, than in controls,
median 10%, range 3–13%, p < 0.001, Figure 2a. Cancer
patients were further divided into two subgroups: those
with metastases to SLN and those with tumor-free SLN. A
higher proportion of Foxp3+ cells were observed in meta-
static SLN, median 20%, range 8–37%, than in SLN with-
out metastasis, median14%, range 8–24%, p = 0.02,
Figure 2b. No difference in the expression of Foxp3+ was
observed between SLN with micro- and macrometastases,
p = 0.64. The proportions of Foxp3+ cells in SLN of node-
negative patients and controls were not significantly dif-
ferent from each other, p = 0.13. Foxp3 expression was a
significant predictor of nodal status, p = 0.001.
The higher proportion of Foxp3+ cells in the SLN of the
cancer patients was neither due to increased infiltration of
CD3+ T-cells nor CD4+ T-cells. The ratio of Foxp3+ cells to
CD3+ cells was higher, 0.24, among the cancer patients
when compared with the ratio of 0.14 in the controls, p <
0.001. Similarly, the ratio of Foxp3+ cells to CD4+ cells was
higher, 0.29, in the cancer patients than in the controls,
0.14, p < 0.001. The ratios of Foxp3+:CD4+  and
Foxp3+:CD3+ were greater in SLN with metastases com-
pared to tumor-free SLN, p < 0.001, Table 2.
IDO+ cells are macrophages located in the perisinusoidal 
areas of SLN
The IDO+ cells were located mainly in the perisinusoidal
areas of the SLN, both around marginal and medullary
sinuses. Most IDO+ cells had the morphologic appearance
of macrophages, Figure 1. IDO+ cells that had a morpho-
logic appearance typical of dendritic cells were only occa-
sionally observed in the paracortical regions of SLN. The
localization of IDO+ cells was similar between SLN from
cancer patients and controls.BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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IDO expression is not associated with SLN status in breast 
cancer
In accordance with Foxp3 expression, a higher frequency
of IDO+  cells was observed in SLN of breast cancer
patients (median 4.0%, range 2.3–6.0%) when compared
to controls (median 1.6%, range 0.8–3.3%), but the dif-
ference was not statistically significant, p = 0.08, Figure 2c.
The median proportion of IDO+ cells in SLN with metas-
tases was 4.0% (range 2.5–6.0%) and the proportion
without metastases was 4.7% (range 2.2–6.5%), p = 0.98,
Figure 2d. IDO expression was not a significant predictor
of nodal status using a logistic regression model, p = 0.42.
Expression of Foxp3 and IDO is correlated in tumor-free 
SLN
The expression of Foxp3 was positively correlated with
that of IDO in SLN of controls, Spearman's rank coeffi-
cient r = 0.69, p = 0.04, as well as in SLN without nodal
metastasis, r = 0.66, p = 0.003. In tumor-positive SLN no
correlation was found, r = 0.16, p = 0.4, Figure 3.
Simultaneous Foxp3 and IDO expression is associated with 
SLN metastases
In order to demonstrate the combined immunosuppres-
sive effect of Foxp3 and IDO, we categorized each SLN
into one of four groups based on whether the SLN was
positive or negative for Foxp3 and IDO. The median pro-
portion of Foxp3+ cells and IDO+ cells in the SLN of the
cancer patients were used as cut-off levels. Values above
19% for Foxp3, and above 4% for IDO were considered
positive. The Foxp3+/IDO+ group consisted almost exclu-
sively of SLN with metastatic disease, whereas the Foxp3-/
IDO- group contained almost all of the control SLN (p =
0.007, Figure 4). Nominal logistic regression analysis
however did not show that IDO improved the predictive
effect of Foxp3 on nodal status.
Discussion
We studied SLN in breast cancer patients and observed an
accumulation of Foxp3+ cells in metastatic lymph nodes.
Previous studies have pointed out that tumor infiltrating
Foxp3 and IDO expression in the sentinel lymph nodes (SLN) Figure 1
Foxp3 and IDO expression in the sentinel lymph nodes (SLN). This figure illustrates the expression of IDO (top row) 
and Foxp3 (bottom row) in a SLN with a 7 mm breast cancer metastasis at 100× (first column), and 400× (second column) 
magnification. Foxp3+ cells are located primarily in the paracortical regions, whereas IDO+ cells infiltrate perisinusoidal areas. 
The pericapsular fat is marked by the circle, the paracortex by the diamond, the marginal sinus by the arrowhead, and the med-
ullary sinus by the diamond.BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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Foxp3 and IDO expression in the sentinel lymph nodes of breast cancer patients and controls Figure 2
Foxp3 and IDO expression in the sentinel lymph nodes of breast cancer patients and controls. The expression of 
Foxp3 is shown as the median percentage of positive cells in the sentinel lymph nodes of breast cancer patients and controls 
(a), and of node-positive, node-negative breast cancer patients and controls (b). The expression of IDO is shown as the median 
percentage of positive cells in the sentinel lymph nodes of breast cancer patients and controls (c), and of node-positive, node-
negative breast cancer patients and controls (d).BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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Foxp3+ Tregs may influence the clinical course of breast
cancer. Bates and co-workers[22] quantified Foxp3+ Tregs
in primary ductal carcinoma in situ (DCIS) and invasive
breast cancer and found that higher numbers of Foxp3+
Tregs in patients with DCIS correlated with increased risk
of relapse. Furthermore, in patients with invasive breast
cancers, infiltration of the primary tumors with Tregs was
associated with lymph node involvement and increased
risk of relapse after five years. Interestingly, a recent study
by Ladoire[23] demonstrated that clinical response to
neoadjuvant therapy with an anthracycline-based regi-
men was associated with a clearance of Foxp3+ cells from
primary tumors. This finding indicates that the immune
system may be involved in eradication of cancer cells in
the context of cytotoxic chemotherapy.
Our results demonstrating Foxp3+ cell infiltration within
metastatic SLN of breast cancer patients are in line with
other studies that correlate high numbers of Tregs with a
metastatic and invasive growth pattern of cancer. In addi-
tion to breast cancer, Tregs may have a role in many other
cancers. In metastatic lymph nodes of patients with
melanoma there are higher frequencies of Tregs than in
tumor-free lymph nodes[24]. In contrast, in ovarian can-
cer fewer Tregs were found in lymph nodes from patients
with advanced stage disease than in earlier stages; how-
ever, accumulation in tumor and ascites was correlated
with more advance stage[2]. In our patient population an
association between accumulation of Foxp3+ cells in SLN
and distant recurrence (data not shown) was not
observed. This may not be surprising, since most of our
patients had tumors with favorable prognostic factors
such that the number of relapses has remained low. Also,
follow-up time was too short to evaluate recurrences after
five years. Our findings are also supported by Matsu-
ura[25] who used quantitative real-time reverse tran-
scriptase-polymer chain reaction to find significantly
higher levels of expression of Foxp3 mRNA in SLN with
metastasis than in those without.
It has recently been shown that IDO expression by plas-
macytoid dendritic cells promotes differentiation of
Foxp3+ Tregs[26]. Furthermore, the expression of IDO has
been correlated with an increase of Foxp3+ cells in multi-
ple murine models [27-29], in human pancreatic adeno-
carcinoma[29], in human uterine cervical carcinoma[30],
and in humans with advanced stages of melanoma fol-
lowing vaccination[31]. Even though few IDO+ cells were
found in the Foxp3+-rich paracortical regions of SLN, IDO
depletes tryptophan and may have regional effect.
Reduced levels of tryptophan activate the amino acid sen-
sitive GCN2-kinase pathway and result in activation of
Tregs[32]. Accordingly, cell-to-cell contact may not be
necessary for IDO+ cells to exert their effect. It is uncertain
if the upregulation of Tregs may be strictly due to IDO, or
tumor or if another mechanism exists.
Based on these reports, we studied the proportion of IDO+
cells in SLN of our patients. Similar to Foxp3 expression,
SLN from breast cancer patients contained higher num-
bers of IDO producing cells; however, the difference
between cancer and control patients was not statistically
significant, and IDO expression did not predict nodal sta-
tus in a regression analysis. In tumor-free SLN of breast
cancer patients and in controls a correlation between
Foxp3+ and IDO+ cells was observed. In contrast, no corre-
lation was found in metastatic lymph nodes suggesting
that the infiltration of breast cancer cells into SLN inter-
feres with the dependence of IDO and Foxp3 on each
other. The expression of IDO may attract or induce Foxp3+
cells prior to nodal metastasis. Localization of IDO+ cells
was not influenced by tumor cell invasion as IDO+ cells
were found in perisinusoidal areas in nonmetastatic and
metastatic SLN. In melanoma patients IDO expression in
SLN has been linked with the immunosuppressive
cytokine IL-10. In these SLN the expression of IDO and IL-
10 was found to be highest in SLN that were infiltrated
with melanoma cells[33]. Another study also found
greater levels of expression of IL-10, IFN-γ, and IDO in
SLN with metastasis than non-SLN in patients with
melanoma[34].
Concurrent expression of IDO and Foxp3 in SLN corre-
lated well with lymph node metastasis. Only 1 out of 12
patients that had high numbers of Foxp3+ and IDO+ cells
in SLN had node negative disease. Furthermore, most
cases of node negative disease and almost all of the con-
trols were in the group with low numbers of Foxp3+ and
IDO+  cells. This finding suggests that IDO may be
involved with the induction of T-cell tolerance in these
patients. However, regression analysis did not demon-
strate a combined predictive effect of Foxp3 and IDO on
Table 2: The mean Foxp3/CD3 and Foxp3/CD4 ratios according to the patient group
Cancer Node positive Node negative Control
Foxp3:CD3* 0.24 0.26 0.17 0.14
Foxp3:CD4* 0.29 0.31 0.19 0.14
Ratio of Foxp3+ cells to that of other T cell markers.
* p < 0.001 for cancer patients compared to controls, and node-positive patients compared to node-negative patients.BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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Correlation of the infiltration of Foxp3+ and IDO+ cells Figure 3
Correlation of the infiltration of Foxp3+ and IDO+ cells. The correlation of Foxp3 and IDO expression of controls (a), 
node-negative (b), and node-positive (c) patients is graphed above. There were significant correlations in the expression of 
both markers between the sentinel lymph nodes of the controls (p = 0.04) and those of patients with tumor-free sentinel 
lymph nodes (p = 0.003).BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
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nodal status. This indicates that the effect of IDO may be
masked by the strong influence of Foxp3+ cells in the
present material.
In this study, immunohistochemistry was used for analy-
sis. Although IHC may be less sensitive and more subjec-
tive in the interpretation than PCR, it allows lymph node
structure to be taken into consideration during analysis.
Due to the use of IHC, we were able to analyze non-met-
astatic regions of SLN whereas PCR does not distinguish
between expression by tumors and immunocytes. The
morphological appearance and distribution of Foxp3+ as
well as IDO+ cells in the lymph node attests to the quality
and reliability of the staining. We found that Foxp3+ cells
were small lymphocytes located in the typical T-cell areas,
while the IDO+ cells were morphologically macrophages
located at perisinusoidal areas.
Conclusion
In conclusion, our study shows that Foxp3+ cells are asso-
ciated with more advanced disease in breast cancer, a find-
ing that is proving to be true in many other cancers. As
IDO has been found to promote differentiation of Tregs,
IDO may become a suitable target to abrogate the devel-
opment of T-cell tolerance and to promote an effective
immune response to breast cancer. Our results about the
combined expression of IDO and Foxp3 in metastastic
SLN support this assumption.
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Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. In 
order to demonstrate the combined immunosuppressive effect of Foxp3 and IDO, we categorized each subject into one of 
four groups based on whether positive or negative for Foxp3 and IDO. The median proportion of Foxp3+ and IDO+ cells in the 
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sively those with nodal disease, (p = 0.007).BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
Page 9 of 10
(page number not for citation purposes)
Acknowledgements
We would like to acknowledge Eija Heilio for her technical assistance in the 
laboratory.
AM was partially supported by grants from the American Scandinavian 
Foundation of Los Angeles and a grant from the Helsinki University Central 
Hospital Research Fund.
AM, PH, ML and KvS were supported by a grant from the Helsinki Univer-
sity Central Hospital Research Fund.
The funding bodies had no role in experiment design, collection, analysis, 
interpretation of data, writing of the manuscript or the decision to submit 
the manuscript for publication.
References
1. Shevach EM: CD4+ CD25+ suppressor T cells: more questions
than answers.  Nat Rev Immunol 2002, 2(6):389-400.
2. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evde-
mon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al.: Specific
recruitment of regulatory T cells in ovarian carcinoma fos-
ters immune privilege and predicts reduced survival.  Nat Med
2004, 10(9):942-949.
3. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner
E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the
regulatory T cell-specific forkhead box transcription factor
FoxP3 is associated with poor prognosis in ovarian cancer.
Clin Cancer Res 2005, 11(23):8326-8331.
4. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H:
Increased populations of regulatory T cells in peripheral
blood and tumor-infiltrating lymphocytes in patients with
gastric and esophageal cancers.  Clin Cancer Res 2003,
9(12):4404-4408.
5. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity
by removing CD25+CD4+ T cells: a common basis between
tumor immunity and autoimmunity.  J Immunol 1999,
163(10):5211-5218.
6. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina
JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine
2,3-dioxygenase by plasmacytoid dendritic cells in tumor-
draining lymph nodes.  J Clin Invest 2004, 114(2):280-290.
7. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor
AL: Inhibition of T cell proliferation by macrophage tryp-
tophan catabolism.  J Exp Med 1999, 189(9):1363-1372.
8. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B,
Brown C, Mellor AL: Prevention of allogeneic fetal rejection by
tryptophan catabolism.  Science 1998, 281(5380):1191-1193.
9. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Exter-
mann M, Mellor AL, Munn DH, Antonia SJ: Indoleamine 2,3-diox-
ygenase contributes to tumor cell evasion of T cell-mediated
rejection.  Int J Cancer 2002, 101(2):151-155.
10. Sakurai K, Amano S, Enomoto K, Kashio M, Saito Y, Sakamoto A, Mat-
suo S, Suzuki M, Kitajima A, Hirano T, et al.: [Study of indoleamine
2,3-dioxygenase expression in patients with breast cancer].
Gan To Kagaku Ryoho 2005, 32(11):1546-1549.
11. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P,
Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, et
al.: Prognostic value of indoleamine 2,3-dioxygenase expres-
sion in colorectal cancer: effect on tumor-infiltrating T cells.
Clin Cancer Res 2006, 12(4):1144-1151.
12. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini
V, Bonanno G, Rutella S, Durelli I, et al.: Modulation of tryptophan
catabolism by human leukemic cells results in the conver-
sion of CD25- into CD25+ T regulatory cells.  Blood 2007,
109(7):2871-2877.
13. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson
M, Mellor AL, Prendergast GC, Munn DH: Inhibition of indoleam-
ine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-
methyl-tryptophan correlates with antitumor responses.
Cancer Res 2007, 67(2):792-801.
14. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy
GP:  Management and survival of female breast cancer:
results of a national survey by the American College of Sur-
geons.  Cancer 1980, 45(12):2917-2924.
15. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: Pathological
prognostic factors in stage I (T1N0M0) and stage II
(T1N1M0) breast carcinoma: a study of 644 patients with
median follow-up of 18 years.  J Clin Oncol 1989, 7(9):1239-1251.
16. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early
breast carcinoma.  Cancer 1994, 74(1 Suppl):381-400.
17. Leidenius MH, Krogerus LA, Toivonen TS, von Smitten KA: Sentinel
node biopsy is not sensible in breast cancer patients with
large primary tumours.  Eur J Surg Oncol 2005, 31(4):364-368.
18. Whiteside TL: Immune suppression in cancer: effects on
immune cells, mechanisms and future therapeutic interven-
tion.  Semin Cancer Biol 2006, 16(1):3-15.
19. Sobin LHWC, editors: TNM classification of malignant tumors.
6th edition. New York: John Wiley and Sons; 2002. 
20. Leidenius MH, Krogerus LA, Toivonen TS, Von Smitten KJ: The fea-
sibility of intraoperative diagnosis of sentinel lymph node
metastases in breast cancer.  J Surg Oncol 2003, 84(2):68-73.
21. Leikola JP, Toivonen TS, Krogerus LA, von Smitten KA, Leidenius MH:
Rapid immunohistochemistry enhances the intraoperative
diagnosis of sentinel lymph node metastases in invasive lob-
ular breast carcinoma.  Cancer 2005, 104(1):14-19.
22. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH:
Quantification of regulatory T cells enables the identification
of high-risk breast cancer patients and those at risk of late
relapse.  J Clin Oncol 2006, 24(34):5373-5380.
23. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B,
Fumoleau P, Ghiringhelli F: Pathologic complete response to
neoadjuvant chemotherapy of breast carcinoma is associ-
ated with the disappearance of tumor-infiltrating foxp3+
regulatory T cells.  Clin Cancer Res 2008, 14(8):2413-2420.
24. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L,
Bachelez H, Kourilsky P, Ferradini L: Foxp3 expressing
CD4+CD25(high) regulatory T cells are overrepresented in
human metastatic melanoma lymph nodes and inhibit the
function of infiltrating T cells.  J Immunol 2004,
173(2):1444-1453.
25. Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T: Mat-
uration of dendritic cells and T-cell responses in sentinel
lymph nodes from patients with breast carcinoma.  Cancer
2006, 106(6):1227-1236.
26. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR: The indoleam-
ine 2,3-dioxygenase pathway is essential for human plasma-
cytoid dendritic cell-induced adaptive T regulatory cell
generation.  J Immunol 2008, 181(8):5396-5404.
27. Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F: Aryl hydro-
carbon receptor signaling mediates expression of indoleam-
ine 2,3-dioxygenase.  Biochem Biophys Res Commun 2008,
375(3):331-335.
28. Yu G, Dai H, Chen J, Duan L, Gong M, Liu L, Xiong P, Wang CY, Fang
M, Gong F: Gene delivery of indoleamine 2,3-dioxygenase pro-
longs cardiac allograft survival by shaping the types of T-cell
responses.  J Gene Med 2008, 10(7):754-761.
29. Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, Park HS, Chang
SH, Cho SG, Min JK, et al.:  Indoleamine 2,3-dioxygenase-
expressing dendritic cells are involved in the generation of
CD4+CD25+ regulatory T cells in Peyer's patches in an
orally tolerized, collagen-induced arthritis mouse model.
Arthritis Res Ther 2008, 10(1):R11.
30. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O,
Saito S: Expression of indoleamine 2, 3-dioxygenase and the
recruitment of Foxp3-expressing regulatory T cells in the
development and progression of uterine cervical cancer.
Cancer Sci 2007, 98(6):874-881.
31. Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer
U, Kaempgen E, Schrama D, Becker JC: Dendritic cell based anti-
tumor vaccination: impact of functional indoleamine 2,3-
dioxygenase expression.  Cancer Immunol Immunother 2007,
56(7):1017-1024.
32. Sharma MD, Baban B, Chandler P, et al.: Plasmacytoid dendritic
cells from mouse tumor-draining lymph nodes directly acti-
vate mature Tregs via indoleamine 2,3-dioxygenase.  J Clin
Invest 2007, 117(9):2570-82.
33. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J,
McCormick D, Jager MJ, Cree IA: Mechanisms of local immuno-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:231 http://www.biomedcentral.com/1471-2407/9/231
Page 10 of 10
(page number not for citation purposes)
suppression in cutaneous melanoma.  Br J Cancer 2007,
96(12):1879-1887.
34. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton
DL, Essner R: Quantitative analysis of melanoma-induced
cytokine-mediated immunosuppression in melanoma senti-
nel nodes.  Clin Cancer Res 2005, 11(1):107-112.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/231/pre
pub